Advertisement


Riccardo Lencioni, MD, on Hepatocellular Carcinoma: Transarterial Chemoembolization, Durvalumab, and Bevacizumab

2024 ASCO GI Cancers Symposium

Advertisement

Riccardo Lencioni, MD, of the University of Pisa School of Medicine, discusses phase III results from the EMERALD-1 study of durvalumab plus bevacizumab plus TACE (transarterial chemoembolization) in patients with embolization-eligible unresectable hepatocellular carcinoma. Compared with TACE alone, this combination is the first immune checkpoint inhibitor–based regimen to improve progression-free survival and has the potential to set a new standard of care in this disease, according to Dr. Lencioni (Abstract LBA432).



Related Videos

Gastrointestinal Cancer
Immunotherapy

Yasunobu Ishizuka, MD, on Gastric Cancer: Does Nivolumab Infusion Time of Day Matter?

Yasunobu Ishizuka, MD, of Japan’s Aichi Cancer Center, discusses study results showing that scheduling infusions of nivolumab monotherapy before mid-afternoon for patients with metastatic gastric cancer may alter treatment efficacy. Several studies have suggested that circadian rhythm is essential in immune system function, including anticancer immunity (Abstract 268).

Colorectal Cancer

Van K. Morris, MD, on Colon Cancer: ctDNA as a Predictive Biomarker

Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results on using circulating tumor DNA (ctDNA) as a predictive biomarker of adjuvant chemotherapy in patients with stage II colon cancer. During the trial, no improvement in ctDNA clearance was observed after 6 months of chemotherapy following resection of disease. Dr. Morris notes that future trials should account for evolving assay performance in patients with colorectal cancer (Abstract 5).

Gastroesophageal Cancer

Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies

Michael K. Gibson, MD, PhD, of Vanderbilt University Medical Center, discusses phase III findings on chemotherapy plus camrelizumab in the ESCORT-NEO trial of patients with resectable esophageal squamous cell carcinoma; and phase III SKYSCRAPER-08 results on first-line tiragolumab plus atezolizumab and chemotherapy in the same patient population (Abstracts LBA244 and 245).

Gastrointestinal Cancer
Neuroendocrine Tumors

Lorraine A. Chantrill, PhD, MBBS, on Gastrointestinal Neuroendocrine Carcinomas: First-Line Treatment With Nab-Paclitaxel Plus Carboplatin

Lorraine A. Chantrill, PhD, MBBS, of Australia’s Wollongong Hospital, New South Wales, discusses phase II findings on the combination of nab-paclitaxel plus carboplatin as a first-line treatment for patients with gastrointestinal neuroendocrine carcinomas. According to Dr. Chantrill, this regimen appears to be active in these tumors and warrants further evaluation in a phase III trial (Abstract 589).

Gastroesophageal Cancer
Gastrointestinal Cancer

Ian Chau, MD, on Gastrointestinal Cancers: Real-World Effectiveness of Nivolumab Plus Chemotherapy

Ian Chau, MD, of The Royal Marsden Hospital, discusses reportedly the first study to evaluate the real-world effectiveness of nivolumab as a first-line treatment of advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma. The combination therapy improved overall survival compared with chemotherapy alone. Dr. Chau presents the 18-month follow-up results (Abstract 295).

Advertisement

Advertisement




Advertisement